Delta Financial Advisors LLC Sells 606 Shares of Amgen Inc. (NASDAQ:AMGN)

Delta Financial Advisors LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 6.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,282 shares of the medical research company’s stock after selling 606 shares during the period. Amgen comprises about 1.2% of Delta Financial Advisors LLC’s investment portfolio, making the stock its 29th biggest holding. Delta Financial Advisors LLC’s holdings in Amgen were worth $2,673,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. grew its holdings in Amgen by 1.7% during the third quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock valued at $3,133,000 after purchasing an additional 193 shares during the period. Diversified Trust Co grew its holdings in Amgen by 76.8% during the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after purchasing an additional 16,376 shares during the period. Nicolet Advisory Services LLC grew its holdings in Amgen by 4.4% during the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock valued at $745,000 after purchasing an additional 117 shares during the period. Platform Technology Partners grew its holdings in Amgen by 7.4% during the third quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock valued at $1,567,000 after purchasing an additional 402 shares during the period. Finally, Traynor Capital Management Inc. grew its holdings in Amgen by 9.5% during the fourth quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock valued at $5,455,000 after purchasing an additional 1,650 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.2 %

AMGN stock traded up $0.47 during midday trading on Thursday, reaching $264.54. 500,576 shares of the company traded hands, compared to its average volume of 2,830,421. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The business has a 50 day moving average of $277.99 and a 200-day moving average of $281.37. The firm has a market capitalization of $141.77 billion, a price-to-earnings ratio of 21.14, a P/E/G ratio of 2.47 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same period in the prior year, the business posted $4.09 earnings per share. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, sell-side analysts expect that Amgen Inc. will post 19.46 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.40%. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent research reports. TD Cowen cut their price target on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday. StockNews.com lowered Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. UBS Group dropped their price objective on Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research note on Wednesday. Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $264.00 to $320.00 in a research note on Thursday, December 21st. Finally, Leerink Partnrs lowered Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Ten investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.